ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

enlonstobart

Also written as “SG001”, “Enlonstobart” and “SYS6041, enlonstobart, bevacizumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Stomach Neoplasms · Uterine Cervical Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pageEnlonstobart: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 16, 202315 company-led studies, 11 open or runningNext primary completion: Jan 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group1410 open or runningphase 3since Jan 16, 2023Feb 20, 2019Apr 2027phase 2 · NCT06136988
Shanghai Runshi Pharmaceutical Technologyits history only11 open or runningphase 2since Nov 9, 2023Nov 9, 2023Jan 30, 2027phase 2 · NCT06132217

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2019First study: phase 1 study in Uterine Cervical NeoplasmsFirst studyNCT03852823 · 192 enrolled · China
  2. Apr 26, 2021Phase 2 study in Uterine Cervical NeoplasmsNCT04886700 · 104 enrolled · China
  3. Jul 16, 2021Phase 2 study in Carcinoma, Ovarian EpithelialNCT04983550 · 126 enrolled
  4. Sep 9, 2021Phase 2 study in Triple Negative Breast NeoplasmsNCT05068141 · 79 enrolled · China
  5. Jan 16, 2023Phase 3 study in RecurrenceNCT05715840 · 368 planned
  6. Jan 19, 2023Named enlonstobartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, SG001
  7. Oct 13, 2023Phase 2 study in Colorectal NeoplasmsNCT06089330 · 102 planned
  8. Nov 8, 2023Phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaNCT06136988 · 129 planned · China
  9. May 12, 2025Phase 2 study in HER2-positive Gastric CancerNCT06998771 · 153 planned
  10. Nov 13, 2025Phase 3 study in Esophageal Squamous Cell CarcinomaNCT07251062 · 737 planned
  11. Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerNCT07332533 · 490 planned
  12. May 31, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07633873 · 500 planned
  13. Jun 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07672223 · 586 planned · China
  14. Jul 8, 2026Phase 2 study in Ovarian NeoplasmsNCT07714668 · 171 planned · China
  15. Oct 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaNCT07924111 · 585 planned

Ahead

  1. Apr 2027Primary completion: phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaNCT06136988
  2. Sep 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07633873
  3. Apr 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT07714668
  4. Jun 30, 2028Primary completion: phase 2 study in HER2-positive Gastric CancerNCT06998771

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

All 14 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07924111Esophageal Squamous Cell Carcinoma3Not yet recruitingDec 30, 2029585
NCT07714668Ovarian Neoplasms · China2RecruitingApr 30, 2028171
NCT07672223Carcinoma, Non-Small-Cell Lung · China3RecruitingSep 30, 2029586
NCT07633873Carcinoma, Non-Small-Cell Lung3Not yet recruitingSep 30, 2027500
NCT07332533HER2-positive Gastric Cancer3Not yet recruitingJun 30, 2032490
NCT07251062Esophageal Squamous Cell Carcinoma3Not yet recruitingDec 30, 2029737
NCT06998771HER2-positive Gastric Cancer2Not yet recruitingJun 30, 2028153
NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma · China2Not yet recruitingApr 2027129
NCT06089330Colorectal Neoplasms2Not yet recruitingJul 2024102
NCT05715840Recurrence3Not yet recruitingJul 31, 2024368
NCT05068141Triple Negative Breast Neoplasms · China2UNKNOWNOct 1, 202279
NCT04983550Carcinoma, Ovarian Epithelial2UNKNOWNJan 2023126
NCT04886700Uterine Cervical Neoplasms · China2UNKNOWNDec 31, 2022104
NCT03852823Uterine Cervical Neoplasms · China1UNKNOWNSep 2022192

How it is read

Names in the registry

  • “SG001”, 8 entries
  • “Enlonstobart”, 3 entries
  • “SYS6041, enlonstobart, bevacizumab”, 1 entry
  • “Enlonstobart injection”, 1 entry
  • “SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.